Liquid Biopsy: A Viable Option for Accurate Diagnosis and Management of Cancer: A Special Emphasis on Prostate and Bladder Cancer

Cancer, a formidable adversary, has long been a source of fear and dread.[1] While significant strides have been made in its treatment and management, early diagnosis and personalized therapy remain elusive.[2] However, a revolutionary approach, liquid biopsy, is emerging as a beacon of hope in the fight against cancer. Liquid biopsy is a minimally/noninvasive diagnostic method that involves the analysis of circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), exosomes, or other tumor-derived molecules found in bodily fluids.[3] The main advantage of liquid biopsy is its ability to detect genetic mutations, alterations, and molecular changes associated with cancer without requiring invasive tissue sampling. This is particularly useful for early detection, monitoring treatment response, detecting minimal residual disease, and identifying therapeutic targets.[4] Conventional cancer diagnosis often relies on tissue biopsies, which can be invasive, painful, discomfort to the patient, and sometimes end with morbidity.[5] Liquid biopsy, on the other hand, offers a less burdensome alternative, patient-friendly approach, requiring only a simple blood draw/urine discharge or any bodily fluid.[6] This makes it particularly appealing for patients who may be frail or unable to undergo invasive procedures. One of the most significant advantages of liquid biopsy is its ability to monitor disease progression in real time. By tracking changes in the levels of CTCs and ctDNA, clinicians can detect early signs of recurrence or resistance to therapy.[4-6] This enables timely adjustments to treatment plans, potentially improving patient outcomes. Moreover, liquid biopsy can help identify specific genetic alterations within the tumor, known as biomarkers, such as exosomes which are small vesicles released by tumors containing proteins, lipids, and RNA.[7] Exosomes carry tumor-related biomarkers and provide information about the tumor’s microenvironment. MicroRNAs (miRNA) such as small RNA molecules that regulate gene expression and can be found in various body fluids.[8] Changes in miRNA profiles can indicate the presence of cancer. These biomarkers can guide the selection of targeted therapies, which are designed to attack cancer cells with specific genetic vulnerabilities. By tailoring treatment to the individual patient’s tumor profile, clinicians can maximize efficacy and minimize side effects.[9] The role of liquid biopsy in the early detection of prostate cancer plays a significant role by detecting tumor-related biomarkers in blood/urine, such as ctDNA and CTCs. It helps identify genetic mutations, including alterations in the androgen receptor gene or BRCA1/2 genes, offering early detection, risk stratification, and prognosis.[10] Liquid biopsy also provides a less invasive alternative to conventional methods such as biopsy and serum prostate-specific antigen testing, improving personalized treatment planning. Liquid biopsy can help detect prostate cancer at an earlier stage, assess the risk of disease progression, and monitor the effectiveness of hormone therapy.[11] Another emerging role of liquid biopsy in diagnosing bladder cancer is by analyzing immunofluorescence markers such as bladder cancer antigen 1 (BLCA1), BLCA4, 5-aminolevulinic acid, and hexaminolevulinate, CTCs, and other urinary biomarkers such as bladder tumor antigen (TRAK) and nuclear matrix protein-22.[12] It offers a noninvasive alternative to conventional cystoscopy and urine cytology for detecting bladder cancer, especially in the early stages.[12] Liquid biopsy can also detect genetic mutations such as FGFR3 and specific miRNA profiles, aiding in early diagnosis and monitoring recurrence. By detecting ctDNA or mutations in urine or blood, liquid biopsy enhances risk stratification and helps assess disease progression, offering a more personalized and less invasive approach to bladder cancer management and monitor the effectiveness of immunotherapy.[13] While liquid biopsy holds immense potential, it is important to acknowledge that it is not without its limitations. The sensitivity of liquid biopsy tests can vary depending on the type of cancer and the stage of the disease. In some cases, the levels of CTCs and ctDNA may be too low to detect, particularly in early-stage cancers.[13] In addition, the interpretation of liquid biopsy results can be complex, requiring specialized expertise. Despite these challenges, liquid biopsy is rapidly evolving, with ongoing research aimed at improving its sensitivity, specificity, and clinical utility. As technology advances and our understanding of cancer biology deepens, liquid biopsy is poised to become an indispensable tool in the fight against this deadly disease. While liquid biopsy holds immense promise, several challenges need to be addressed. These include standardizing methodologies, improving sensitivity and specificity, and developing cost-effective assays. As research progresses, we can anticipate further refinement of liquid biopsy techniques, making them an invaluable tool in the management of various malignancies, including prostate and bladder cancer.